HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Philippe Moreau Selected Research

Therapeutics

5/2024Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial.
3/2024Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study.
2/2024Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone.
1/2024Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX.
1/2024GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
12/2023Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
12/2023Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
12/2023Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study.
12/2023Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group.
12/2023A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Philippe Moreau Research Topics

Disease

335Multiple Myeloma
05/2024 - 01/2002
73Neoplasms (Cancer)
04/2024 - 01/2003
39Disease Progression
03/2024 - 11/2005
23Infections
01/2024 - 12/2005
19Thrombocytopenia (Thrombopenia)
10/2023 - 04/2013
19Neutropenia
10/2023 - 08/2009
18Peripheral Nervous System Diseases (PNS Diseases)
02/2021 - 08/2009
17Residual Neoplasm
03/2024 - 11/2012
12Chromosome Aberrations (Chromosome Abnormalities)
03/2024 - 10/2010
11Pneumonia (Pneumonitis)
10/2023 - 10/2013
9Inflammation (Inflammations)
04/2024 - 02/2003
9Hematologic Neoplasms (Hematological Malignancy)
11/2023 - 12/2004
8Graft vs Host Disease (Graft-Versus-Host Disease)
01/2024 - 01/2010
8Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
11/2023 - 11/2005
8Hypoxia (Hypoxemia)
08/2023 - 04/2007
8Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2021 - 08/2003
8Melanoma (Melanoma, Malignant)
01/2018 - 10/2003
7Malaria
01/2022 - 06/2013
7Lymphopenia (Lymphocytopenia)
11/2021 - 10/2014
6Sepsis (Septicemia)
10/2023 - 12/2009
6Lymphoma (Lymphomas)
10/2021 - 03/2002
6Fatigue
01/2020 - 10/2013
6Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2019 - 03/2002
6Virus Diseases (Viral Diseases)
01/2017 - 01/2003
5Vomiting
01/2023 - 03/2012
5Immunoglobulin Light-chain Amyloidosis
10/2020 - 11/2004
5Smoldering Multiple Myeloma
05/2020 - 10/2017
5Choriocarcinoma
10/2019 - 11/2003
4Septic Shock (Toxic Shock Syndrome)
10/2023 - 10/2017
4Cytokine Release Syndrome
03/2023 - 01/2023
4Nausea
01/2023 - 03/2012
4Hypertension (High Blood Pressure)
10/2021 - 01/2016
4Monoclonal Gammopathy of Undetermined Significance
01/2021 - 01/2017
4Pain (Aches)
01/2021 - 04/2008
4Leukemia
01/2019 - 07/2012
4Anemia
01/2019 - 10/2016
3Glioma (Gliomas)
01/2023 - 02/2013
3Plasmacytoma
11/2022 - 01/2013
3Bone Diseases (Bone Disease)
01/2022 - 03/2014
3Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
10/2021 - 01/2019
3Diarrhea
08/2020 - 03/2017
3Febrile Neutropenia
05/2020 - 04/2013
3Myelodysplastic Syndromes (Myelodysplastic Syndrome)
11/2019 - 09/2014

Drug/Important Bio-Agent (IBA)

151Dexamethasone (Maxidex)FDA LinkGeneric
05/2024 - 11/2006
82Bortezomib (Velcade)FDA Link
05/2024 - 11/2006
77Lenalidomide (CC 5013)FDA Link
02/2024 - 05/2008
47HLA-G Antigens (HLA G)IBA
08/2023 - 01/2003
45carfilzomibIBA
03/2024 - 04/2014
40Proteasome InhibitorsIBA
12/2023 - 08/2012
39daratumumabIBA
01/2024 - 06/2016
35pomalidomideIBA
03/2024 - 03/2013
29Monoclonal AntibodiesIBA
03/2024 - 09/2007
28Thalidomide (Thalomid)FDA Link
01/2023 - 01/2002
25isatuximabIBA
03/2024 - 12/2019
22ixazomibIBA
02/2024 - 08/2014
21Melphalan (Alkeran)FDA LinkGeneric
01/2023 - 02/2002
20Proteins (Proteins, Gene)FDA Link
01/2024 - 11/2005
16Immunomodulating AgentsIBA
03/2024 - 07/2013
11PanobinostatIBA
01/2021 - 07/2013
11HLA Antigens (Human Leukocyte Antigens)IBA
01/2021 - 11/2005
9B-Cell Maturation AntigenIBA
04/2024 - 01/2020
8Immunoglobulins (Immunoglobulin)IBA
01/2023 - 12/2014
8elotuzumabIBA
01/2023 - 06/2012
8Cyclophosphamide (Cytoxan)FDA LinkGeneric
04/2021 - 02/2015
7selinexorIBA
05/2024 - 01/2019
7venetoclaxIBA
11/2021 - 04/2015
6AntibodiesIBA
12/2023 - 01/2021
6Chimeric Antigen ReceptorsIBA
03/2023 - 12/2019
6Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
01/2023 - 11/2009
6Prednisone (Sone)FDA LinkGeneric
01/2019 - 11/2008
5bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA
04/2024 - 01/2021
5Bispecific AntibodiesIBA
01/2024 - 01/2022
5Biomarkers (Surrogate Marker)IBA
01/2022 - 12/2018
5CytokinesIBA
01/2021 - 10/2003
5Doxorubicin (Adriamycin)FDA LinkGeneric
01/2021 - 07/2009
4idecabtagene vicleucelIBA
04/2024 - 01/2021
4AntigensIBA
03/2024 - 11/2005
4L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
01/2023 - 07/2014
4Alkylating AgentsIBA
01/2023 - 02/2010
4Immunoglobulin G (IgG)IBA
01/2022 - 09/2013
4Histone Deacetylase InhibitorsIBA
01/2018 - 07/2013
43' Untranslated Regions (3' UTR)IBA
01/2017 - 06/2013
4Messenger RNA (mRNA)IBA
09/2016 - 10/2005
3Immunoconjugates (Immunoconjugate)IBA
10/2023 - 01/2020
3DNA (Deoxyribonucleic Acid)IBA
08/2023 - 09/2008
3dabrafenibIBA
01/2023 - 07/2020
3trametinibIBA
01/2023 - 07/2020
3VaccinesIBA
01/2023 - 12/2021
3MicroRNAs (MicroRNA)IBA
01/2020 - 01/2015

Therapy/Procedure

141Therapeutics
05/2024 - 01/2002
61Stem Cell Transplantation
01/2023 - 02/2002
24Transplantation
12/2023 - 05/2008
22Drug Therapy (Chemotherapy)
12/2021 - 09/2002
9Hematopoietic Stem Cell Transplantation
05/2022 - 12/2004
6Immunotherapy
03/2024 - 09/2016
5Autologous Transplantation
01/2014 - 11/2008
4Subcutaneous Injections
11/2022 - 12/2008
4Intravenous Administration
10/2022 - 12/2008
3Salvage Therapy
01/2023 - 12/2004
3Cell Transplantation
01/2020 - 02/2015